within Pharmacolibrary.Drugs.ATC.C;

model C08CA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.0008166666666666667,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.07,
    k12             = 41,
    k21             = 41
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08CA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Isradipine is a dihydropyridine calcium channel blocker used primarily for the management of hypertension (high blood pressure). It acts by relaxing vascular smooth muscle, leading to decreased peripheral resistance and lowered blood pressure. Isradipine was previously approved and marketed for clinical use but is now discontinued in several countries, including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration of immediate-release isradipine tablets.</p><h4>References</h4><ol><li><p>Venuto, CS, et al., &amp; Simuni, T (2021). Isradipine plasma pharmacokinetics and exposure-response in early Parkinson&#x27;s disease. <i>Annals of clinical and translational neurology</i> 8(3) 603–612. DOI:<a href=&quot;https://doi.org/10.1002/acn3.51300&quot;>10.1002/acn3.51300</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33460320/&quot;>https://pubmed.ncbi.nlm.nih.gov/33460320</a></p></li><li><p>Clifton, GD, et al., &amp; Foster, TS (1988). The pharmacokinetics of oral isradipine in normal volunteers. <i>Journal of clinical pharmacology</i> 28(1) 36–42. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1988.tb03098.x&quot;>10.1002/j.1552-4604.1988.tb03098.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2965165/&quot;>https://pubmed.ncbi.nlm.nih.gov/2965165</a></p></li><li><p>Bobbala, SK, &amp; Veerareddy, PR (2012). Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. <i>Journal of liposome research</i> 22(4) 285–294. DOI:<a href=&quot;https://doi.org/10.3109/08982104.2012.697067&quot;>10.3109/08982104.2012.697067</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22762199/&quot;>https://pubmed.ncbi.nlm.nih.gov/22762199</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08CA03;
